J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...

Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the ...

HealthDay News — Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study published online Nov. 27 in Nutrients.

SaveHealth reports on eczema medications, detailing various options from topical treatments to advanced therapies for ...

A 28-year-old woman presented to her primary care provider with the chief report of persistent itch associated with atopic dermatitis (AD), with itch severity worst on her hands bilaterally. AD was ...

Please provide your email address to receive an email when new articles are posted on . Percentages of patients with at least one atopic comorbidity ranged from 69.9% to 75.4%. Percentages of patients ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...

Despite living with severe eczema all her life, one woman achieved her dream of being a fashion designer and found a treatment that works for her. Different atopic ...

A 58-year-old Caucasian man with melanoma was started on treatment with the anti-PD-1 immune checkpoint inhibitor (ICI) pembrolizumab (Keytruda, 200 mg every 21 days) after the cancer metastasized. He ...

Please provide your email address to receive an email when new articles are posted on . Food allergy rates included 38.3% with asthma and 20.4% with no asthma. Atopic dermatitis was more severe among ...

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled ...